Ixazomib

7:37
Prevention and management of adverse events in relapsed myeloma
Michel Delforge
1:01
Updates in amyloidosis: ISA 2020
Joan Bladé
3:02
Consolidation therapy options for myeloma post-transplant
Philip McCarthy
2:45
Myeloma: real-world data
Evangelos Terpos
3:59
Promising combination of ixazomib, lenalidomide & dex in high-risk smoldering myeloma
Mark Bustoros
04:22
Mohamad Mohty’s myeloma highlights from ASH 2018
Mohamad Mohty
3:31
MAIA & TOURMALINE-MM3: updates in newly diagnosed multiple myeloma
Noopur Raje
1:58
Renal response to carfilzomib vs. bortezomib in R/R MM in the real world
Noopur Raje
1:44
Recent clinical trial updates for smoldering multiple myeloma
Irene Ghobrial
6:36
The definitive guide to multiple myeloma at ASH 2018: part V
Mohamad Mohty et al.
01:27
Ixazomib prolongs PFS following ASCT in newly diagnosed myeloma
Vincent Rajkumar
1:08
Quadruplet regimens and antibodies for newly diagnosed multiple myeloma
Noopur Raje
2:22
Update on recent smoldering multiple myeloma trials
Maria-Victoria Mateos
4:58
OPTIMISMM: investigating an alternative therapy for lenalidomide-refractory patients
Paul Richardson
2:20
Do results obtained in clinical trials translate accurately in real world practice?
Paul Richardson
2:58
Immunomodulatory drug combinations for multiple myeloma
Niels van de Donk
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals